Translational cancer research programme
Description
Cancer is one of the leading causes of illness and death worldwide. It causes around ten million estimated deaths per year.
In recent years, patients’ survival rate and quality of life have improved thanks in part to personalised medicine—targeted new therapies that take a more individualised approach to each patient. However, there are still many medical needs to be met, such as identifying patients at higher risk of developing cancer, understanding the mechanisms that produce resistance to therapies and finding markers indicating patients with greater therapeutic benefits.
The Transitional Research in Cancer programme encompasses six research groups of excellence at IDIBAPS and aims to improve our understanding of cancer to better prevent, diagnose and treat it while promoting accurate oncology. With this goal in mind, the researchers involved in the programme will use innovative biomedical technologies such as artificial intelligence, big data analysis, cell sequencing, spatial transcriptomics and cutting-edge pre-clinical models with cultures of human samples.
Goals
- Define populations at risk of developing cancer using artificial intelligence algorithms and genomic data
- Define determinants of response and resistance to molecular therapies and immunotherapies
- Develop strategies to overcome resistance using both tissue samples from treated patients and new pre-clinical models
Coordinators
Groups
-
Translational research in hepatic oncology
Josep M. Llovet -
Gene therapy and cancer
Cristina Fillat -
Gastrointestinal and pancreatic oncology
Antoni Castells -
Melanoma: imaging, genetics and immunology
Susana Puig -
Genetic predisposition to gastrointestinal cancer
Sergi Castellví-Bel -
Translational colorectal cancer genomics
Jordi Camps -
Molecular pathology of inflammatory conditions and solid tumours
Miriam Cuatrecasas